Scientific Industries Launches DOTS MPS for Cell Culture Biopharma Market, Reports 24% Bioprocessing Revenue Growth
Key Insights
Scientific Industries (search) reported 24% revenue growth in its Bioprocessing Systems (search) Operations, driven primarily by the newly launched DOTS MPS (search) system which expanded into the mammalian cell culture biopharma market.
The company reduced its total net losses by 29% through operational efficiencies, while launching the new VIVID WORKSTATION (search) automated pill counter with plans for AI capabilities by the end of 2025.
Scientific Industries (search) is positioning its DOTS MPS (search) as a cost-effective data platform for pharmaceutical companies, with ongoing trials at six major pharma companies and plans to launch new optical pH sensors and liquid injection systems in 2025.
Scientific Industries (search), Inc. (OTCQB: SCND), a life sciences tool provider specializing in bioprocessing products, has reported significant growth in its bioprocessing operations for the fiscal year ended December 31, 2024, driven by the successful expansion of its DOTS MPS (search) system into the mammalian cell culture biopharma market.
The company's Bioprocessing Systems (search) Operations recorded a 24% increase in net sales, reaching $1.7 million compared to $1.4 million in the previous year. Approximately 70% of these sales were attributed to the newly launched DOTS MPS (search) system, which is now being trialed by six of the world's largest pharmaceutical companies.
Bioprocessing Growth Amid Overall Financial Improvements
Despite a 3.6% decrease in total net revenues to $10.7 million, Scientific Industries (search) managed to reduce its net loss by 29% to $6.4 million ($0.61 per share), compared to $9.1 million ($1.27 per share) for the previous fiscal year. This improvement was primarily achieved through operational efficiencies and working capital management initiatives implemented in early 2024.
"2024 marked a milestone with the first commercial impact of our $30 million investment in the DOTS MPS (search) system," said John Moore, Chairman of Scientific Industries (search). "Our new platform is priced 2.5x higher than our legacy CGQ product, thanks to enhanced features. DOTS also delivers recurring revenue from our software suite and a growing range of single-use sensors."
The company's strategic focus on bioprocessing innovation comes at a time when pharmaceutical companies are increasingly seeking cost-effective, reliable data platforms to drive AI and digital biology advancements.
Expanding into High-Value Biopharma Markets
A key development highlighted in the financial report is the Q1 2025 upgrade that allows the DOTS MPS (search) system to monitor mammalian cells, which are essential to high-value biopharma markets including monoclonal antibodies (search), cell and gene therapy (search), and RNA (search).
Helena Santos, Chief Executive Officer of Scientific Industries (search), expressed confidence in the company's product roadmap: "This strong performance underscores the positive momentum and strengthens our confidence in the product developments slated for launch in 2025. These innovative bioprocessing products are laying a solid foundation for the Company's substantial growth in the coming years."
The company plans to complete its base product in 2025 while launching a first-in-class optical pH sensor (search) and high-performance liquid injection system in the second half of the year.
Diversified Product Portfolio with AI Integration
Beyond its bioprocessing operations, Scientific Industries (search) recently launched the VIVID WORKSTATION (search) automated pill counter, with plans to introduce a machine learning (AI) model by the end of 2025. This "All-in-one Pill Counter" combines high-precision counting with a powerful PC, enabling pharmacists to manage workflows and run pharmacy software on a single machine.
The company's Benchtop Laboratory Equipment Operations (search), which includes the Genie (search) and Torbal (search) divisions, experienced a 7% decrease in net revenues to $9.0 million. This decline was attributed to reduced VIVID pill counter sales, primarily due to regulations related to pharmacy direct and indirect remuneration fees that caused financial challenges for independent pharmacies in early 2024.
Financial Position and Outlook
As of December 31, 2024, Scientific Industries (search) reported cash, cash equivalents, and investments totaling $2.6 million, with working capital of $6.5 million. The company's gross profit for the fiscal year was $4.7 million, representing a profit margin of 44.2%.
Operating expenses decreased significantly by $3.0 million (21%) to $11.4 million, reflecting the company's focus on cost reduction and operational efficiency.
"We are strategically positioning the Company to offer a range of AI-enabled or enabling products in the future," Santos noted, highlighting the synergy between the VIVID WORKSTATION (search) and the company's portfolio of bioprocessing products.
With its opportunity pipeline having tripled compared to the previous year, Scientific Industries (search) appears well-positioned to capitalize on the growing demand for digitally simplified bioprocessing tools in the pharmaceutical and life sciences sectors.